Navigation Links
Genesis Biopharma Issues Letter To Shareholders
Date:5/21/2012

results.

To support the commercial development plan for our ACT, we engaged four leading consultants to provide key services in cell therapy bioprocess engineering, clinical trial design, biostatistics, regulatory affairs and FDA compliance.  This dynamic team has been instrumental in developing our clinical strategy to advance our ACT on a regulatory pathway toward approval.

One of the prerequisites for a successful IND filing is confirmation of our ability to manufacture our investigational ACT treatment in accordance with good clinical practice ("GCP"). Our goal is to ensure our GCP process will be consistent with the approach we propose to take for the manufacture of commercial product  As previously reported we entered into a process development and scale-up agreement relating to the manufacture of Contego with Lonza, which is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries.  Over the past months we have made significant progress in taking the Standard Operating Procedures (SOPs) currently used by the institutions conducting the physician-sponsored studies, and replicating them to build scaled-up bioprocesses that can support the commercial manufacture of Contego.  Our goal is to complete the technology transfer to Lonza and obtain FDA certification for a commercial-scale TIL manufacturing processes to be ready to commence Registration trails in late 2013. 

We are very satisfied with the progress we've made to date, and expect the remainder of 2012 to be an equally productive time.  We are delighted to be working with several of the world's leading oncologists and clinical cancer-care institutions to bring our ACT through the regulatory process with the goal of expanding access to this life-saving therapy to the thousands of patients with late-stage melanoma who have no other treatment options.

On behalf of my colleagues and our Board of Directors, tha
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
2. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
3. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
4. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
5. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
6. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
8. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
9. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
10. Genesis Biopharma Names David Voyticky to Board of Directors
11. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 ... ) has announced the addition of ... & Stable Isotopes Market [SPECT/PET Radioisotopes ... Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, ... report to their offering. ...
(Date:6/18/2013)... 18, 2013 PathoGenetix, Inc. ... for rapid bacterial strain typing, announced today that ... company as Vice President of Engineering. Dr. Luckey ... company’s RESOLUTION™ Microbial Genotyping System . The ... instrument, pathogen-specific assay kits, database and software, will ...
(Date:6/18/2013)... UT (PRWEB) June 18, 2013 NuView ... generation imaging and in vitro diagnostic (IVD) biomarkers, today ... NuView’s novel urine screen in development for the early ... was presented in an oral presentation at the 2013 ... Molecular Imaging (SNMMI) in Vancouver, Canada on Sunday, June ...
(Date:6/17/2013)... Miami, FL (PRWEB) June 17, 2013 As ... Action are committed to finding a cure all for acne, ... Month, the AARS (Acne and Rosacea Society) ... skin conditions, and helping to educate the public on treatment ... leading society by announcing their daily news updates via social ...
Breaking Biology Technology:North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 2PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System 3NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 3Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions 2
... more tech companies by offering tax credits, bringing the ... , ,Governor Jim Doyle on Monday added three biotechs, one ... state's Act 255 was passed last year to ... tax credits for investors. , ,This week's five companies were: ...
... Health and Human Services secretary and longtime Wisconsin governor, ... leaving his Cabinet post in January. , ,Thompson accepted ... Deloitte & Touche USA; law partner at Washington power ... of La Crosse-based Logistics Health Inc., a privately held ...
... Researchers led by James Dahlberg, a founder of Madison-based ... a super-small genetic element may play a critical role in ... by Dahlberg and collaborator Wayne Tam at the Joan and ... week in the Proceedings of the National Academy of Sciences ...
Cached Biology Technology:Tommy Thompson tackles the private sector in spades 2Third Wave co-founder shoots for small target in latest project 2
(Date:6/18/2013)... shows that weight gain and increased head size in the first ... at early school age. , The study was led by University ... 13,800 children who were born full-term. , The results, published in ... put on 40% of their birthweight in the first four weeks ... six years of age, compared with babies who only put on ...
(Date:6/17/2013)... eat their food may turn out to be just as ... out of St. Michael,s Hospital. , The study, led ... association between poor eating habits in kids ages three ... cholesterol, putting them at risk for cardiovascular disease later ... Canadian Medical Association Journal today. , "We know ...
(Date:6/17/2013)... help delay early onset of puberty in girls, a ... at The Endocrine Society,s 95th Annual Meeting in San ... ages of 10 and 14. Boys undergo these changes ... Precocious puberty is diagnosed in girls when sexual development ... is diagnosed when these changes occur before age 9. ...
Breaking Biology News(10 mins):IQ link to baby's weight gain in first month 2Poor eating behaviors may put preschoolers at risk for later health problems 2Vitamin D supplementation may delay precocious puberty in girls 2
... Germany, November 14, 2011 DERMALOG Identification ... set a new world record in the identification of ... AFIS", is capable of correctly identifying the ten fingerprints ... of more than 129 million fingerprints. The renowned international ...
... Hospitals Case Medical Center researchers could still be close ... as they originally thought. LateTIME was a study ... that were believed to have the ability to improve ... heart within two weeks of the attack. Results are ...
... from heart failure due to a previous myocardial infarction ... following an investigative treatment that involved infusing them with ... percent improvement average the researchers projected for the Phase ... today (Nov. 14) in The Lancet and ...
Cached Biology News:World Record in Fingerprint Identification: DERMALOG Correctly Identifies 129 Million Fingerprints in one Second 2World Record in Fingerprint Identification: DERMALOG Correctly Identifies 129 Million Fingerprints in one Second 3Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2Results triple researchers' projections with use of adult stem cells for heart failure 2